Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ipragliflozin + metformin
- Development stage
- Unknown
- Lead developer
- Astellas Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ipragliflozin + metformin is an oral fixed-dose combination drug used in the management of type 2 diabetes mellitus. The combination harnesses two complementary mechanisms to improve glycemic control: metformin, a biguanide, reduces hepatic glucose production and increases insulin sensitivity, while ipragliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, reduces renal glucose reabsorption, facilitating urinary glucose excretion. Clinical data demonstrate improved efficacy and safety for the combination versus metformin monotherapy, providing better glucose and HbA1c control with a low risk of hypoglycemia[1][2][3][4].
- Other names
- ASP1941 + metforminipragliflozin + metformin
02
Targets
ND1 (Mitochondrial electron transport chain complex I)DAT (Dopamine plasma membrane transport protein)HTR2B (5-Hydroxytryptamine Receptor 2B)SGLT2 (Sodium-glucose cotransporter protein subunit 2)
Beyond the preview
Go deeper on ipragliflozin + metformin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ipragliflozin + metformin.